Compare FND & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | NUVL |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.1B |
| IPO Year | 2014 | 2021 |
| Metric | FND | NUVL |
|---|---|---|
| Price | $66.62 | $100.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $78.81 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 2.3M | 444.7K |
| Earning Date | 05-22-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $4,684,088,000.00 | N/A |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $9.57 | $714.21 |
| P/E Ratio | $34.82 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $55.11 | $55.54 |
| 52 Week High | $95.83 | $113.02 |
| Indicator | FND | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 43.80 |
| Support Level | $65.96 | $98.65 |
| Resistance Level | $73.04 | $106.97 |
| Average True Range (ATR) | 3.38 | 4.49 |
| MACD | -0.26 | -0.18 |
| Stochastic Oscillator | 36.81 | 28.74 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.